Studies on new antibiotic lividomycins. V. In vitro and in vivo antimicrobial activity of lividomycin A.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects*; D001798:Blood Proteins; D003091:Colistin / Q000494:pharmacology; D003470:Culture Media; D004352:Drug Resistance, Microbial; D004927:Escherichia coli Infections / Q000188:drug therapy; D005839:Gentamicins / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D007612:Kanamycin / Q000494:pharmacology / Q000627:therapeutic use; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008826:Microbial Sensitivity Tests; D011485:Protein Binding; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects; D013307:Streptomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D003470:Culture Media; D005839:Gentamicins; D007612:Kanamycin; D013307:Streptomycin; D003091:Colistin